Description: Kyowa Hakko Kirin Co., Ltd., a research and development-based life sciences company, manufactures and markets pharmaceuticals and bio-chemicals worldwide. Its products include ABSTRAL, a novel sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; GRAN, a human colony-stimulating factor; and G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia. The company's products also comprise LEUNASE for acute lymphoblastic leukemia; Mitomycin-C, an anticancer antibiotic; Moventig for the treatment of opioid induced constipation in adult patients; PecFent, a nasally administrated spray; and REGPARA, a new class of agent for the treatment of secondary hyperparathyroidism. In addition, it offers Romiplate/Nplate, a genetically recombinant protein, which stimulates platelet production through the stimulation of thrombopoietin receptors; and SANCUSO for the treatment for nausea and vomiting. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Hakko Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
Home Page: www.kyowakirin.com
Otemachi Financial City Grand Cube
Tokyo,
100-0004
Japan
Phone:
81 3 5205 7200
Officers
| Name | Title |
|---|---|
| Mr. Masashi Miyamoto Ph.D. | President, CEO & Representative Director |
| Mr. Motohiko Kawaguchi | CFO & Managing Executive Officer |
| Mr. Yutaka Osawa M.B.A. | CCO, Executive VP & Representative Director |
| Kazuki Nemoto | Head of Global Legal |
| Hiroki Nakamura | Global Corporate Communications Head |
| Hiroshi Sonekawa | Managing Executive Officer, VP and Head of Sales & Marketing Division |
| Ms. Shoko Itagaki | Executive Officer & Chief People Officer |
| Mr. Takeyoshi Yamashita Ph.D. | Chief Medical Officer, Senior Managing Executive Officer & Director |
| Yasuo Fujii M.B.A. | Chief Strategy Officer, VP & Managing Executive Officer |
| Jean-David Rafizadeh-Kabe J.D., M.D. | Head of Global Operational Transformation |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 15.8479 |
|---|---|
| Trailing PE: | 15.5825 |
| Price-to-Book MRQ: | 1.4825 |
| Price-to-Sales TTM: | 0.017 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 5974 |